Review



braf multitarget tki (vegfr, raf, pdgfr)  (MultiTarget Pharmaceuticals)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    MultiTarget Pharmaceuticals braf multitarget tki (vegfr, raf, pdgfr)
    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
    Braf Multitarget Tki (Vegfr, Raf, Pdgfr), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf multitarget tki (vegfr, raf, pdgfr)/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    braf multitarget tki (vegfr, raf, pdgfr) - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?"

    Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

    Journal: ESMO Open

    doi: 10.1016/j.esmoop.2022.100638

    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " title="Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or ... " property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21

    Techniques Used: Homologous Recombination, Control

    Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC
    Figure Legend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

    Techniques Used: Clinical Proteomics, Mutagenesis, Expressing



    Similar Products

    braf multitarget tki (vegfr, raf, pdgfr)  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals braf multitarget tki (vegfr, raf, pdgfr)
    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
    Braf Multitarget Tki (Vegfr, Raf, Pdgfr), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/braf multitarget tki (vegfr, raf, pdgfr)/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    braf multitarget tki (vegfr, raf, pdgfr) - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    multitarget vegfr-tkis  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals multitarget vegfr-tkis
    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
    Multitarget Vegfr Tkis, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/multitarget vegfr-tkis/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    multitarget vegfr-tkis - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    vegfr-tki multitarget  (MultiTarget Pharmaceuticals)
    90
    MultiTarget Pharmaceuticals vegfr-tki multitarget
    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="250" height="auto" />
    Vegfr Tki Multitarget, supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegfr-tki multitarget/product/MultiTarget Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    vegfr-tki multitarget - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, <xref ref-type= 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21 " width="100%" height="100%">

    Journal: ESMO Open

    Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

    doi: 10.1016/j.esmoop.2022.100638

    Figure Lengend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, 15 and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. 21

    Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

    Techniques: Homologous Recombination, Control

    Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

    Journal: ESMO Open

    Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

    doi: 10.1016/j.esmoop.2022.100638

    Figure Lengend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

    Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

    Techniques: Clinical Proteomics, Mutagenesis, Expressing